EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer

Ovarian Cancer Recurrent Clinical Trial

— ESP2011-002  

Official title:

EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01485848
• Other study ID #: ACT12601
• Secondary ID: U1111-1124-2062
• Status: Completed
• Phase: Phase 2
• First received: December 2, 2011
• Last updated: June 9, 2014
• Start date: February 2012
• Est. completion date: May 2014

Study information

• Verified date: June 2014
• Source: Esperance Pharmaceuticals Inc
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Primary Objectives: o Run-in Phase: Determine a dose of EP-100 at which the initial benefit/risk of paclitaxel combined with EP-100 can be studied. o Randomized Phase: Compare the anti-tumor effects of EP-100 combined with weekly paclitaxel versus paclitaxel alone in patients with ovarian cancer. Secondary Objectives: o Randomized Phase: Quantify any significant changes in the safety profile of weekly paclitaxel alone compared to the doublet combination of paclitaxel with EP-100. o Determine an initial benefit/risk profile for this new drug combination.

Description:

Total duration of the study for each participant is 9 to 10 months, consisting of a 1 month screening period, a 6 to 7 months treatment period, and a 30 day follow-up. All patients with stable disease or who have achieved partial or complete response and for whom dosing has been safe and reasonably well-tolerated may continue additional treatment cycles on the same regimen. Any patient whose imaging assessment shows disease progression after receiving at least two cycles of single agent weekly paclitaxel on ARM 1 may then be offered treatment with the combination of EP-100 plus paclitaxel in the same dose regimen as ARM 2.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 49
• Est. completion date: May 2014
• Est. primary completion date: May 2014
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Adult patients with histologically confirmed epithelial ovarian carcinomas; these will include primary peritoneal and fallopian tube carcinomas. Patient's tumor shown to be positive for the LHRH-receptors by standardized immunocytochemistry performed at the study's central laboratory.

• Reliable cancer treatment history documenting advanced disease in patients who have progressed during or recurred after treatment with a paclitaxel and/or platinum regimen for advanced disease.

• Evaluable disease based on criteria of the Gynecologic Intergroup Response Evaluation Criteria in in Solid Tumors.

• Karnofsky performance status >/= 70%.

Exclusion criteria:

• Significant cardiac disease.

• Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy.

• Pregnant or nursing women.

• Treatment with radiation therapy or investigational therapy within 4 weeks prior to Day 1. Had received chemotherapy prior to study entry equivalent to 3 to 5 half-lives of that chemotherapy agent or 4 weeks prior to study entry (whichever is shorter) with resolution of any side effects from that previous therapy (6 weeks for nitrosoureas or Mitomycin C.)

• Subjects with known central nervous system (CNS) metastases, either previously treated or current.

• Disease-free and off therapy for any other cancer within 5 years, except for adequately treated basal cell or squamous cell skin cancer or cervical intraepithelial neoplasia (CIN).

• Had major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1. o Had minor surgery (superficial incisions unlikely to obscure bleeding or infections) within 2 weeks prior to Day 1.

• Potentially life-threatening disease (hypercalcemia, spinal cord compression) whose disease may progress acutely during therapy.

• Unwilling or unable to comply with procedures required in this protocol.

• Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.

• Susceptibility to histamine release.

• Chronic treatment with corticosteroids.

• Baseline QTc exceeding 450 msec (by Bazett's formula) and/or patients receiving class 1A or class III antiarrythmic agents.

• Serious nonmalignant disease.

• Subjects who are currently receiving any other investigational agent.

• Inadequate renal and liver functions and bone marrow reserve.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Ovarian Cancer Recurrent
• Ovarian Neoplasms

Intervention

Drug:
• EP-100
Pharmaceutical form:Solution Route of administration: Intravenous
• Paclitaxel
Pharmaceutical form:Solution Route of administration: Intravenous

Locations

Country	Name	City	State
United States	Investigational Site Number 840503	Bozeman	Montana
United States	Investigational Site Number 840010	Covington	Louisiana
United States	Investigational Site Number 840001	Greenbrae	California
United States	Investigational Site Number 840006	Houston	Texas
United States	Investigational Site Number 840603	Kennewick	Washington
United States	Investigational Site Number 840007	Louisville	Kentucky
United States	Investigational Site Number 840004	Middletown	Ohio
United States	Investigational Site Number 840103	Mount Vernon	Washington
United States	Investigational Site Number 840008	Portland	Oregon
United States	Investigational Site Number 840005	San Francisco	California
United States	Investigational Site Number 840003	Seattle	Washington
United States	Investigational Site Number 840403	Seattle	Washington
United States	Investigational Site Number 840011	Shreveport	Louisiana
United States	Investigational Site Number 840303	Tacoma	Washington
United States	Investigational Site Number 840203	Wenatchee	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Esperance Pharmaceuticals Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with dose limiting toxicities (DLTs) at different doses		Up to 30 weeks	Yes
Primary	Overall Response Rate (ORR)		Up to 30 weeks	No
Secondary	Time to Progression (TTP) - Time		Up to 18 months	No
Secondary	Progression-free Survival - Time		Up to 18 months	No
Secondary	Overall Survival (OS) - Time		Up to 18 months	No
Secondary	Duration of Response - Time		Up to 18 months	No
Secondary	Number of Participants with Adverse Events		Up to 18 months	Yes